# US 2018/0362427 A1 · New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0362427 A1
- Document ID: US20180362427A1
- Status: Published application
- Kind: A1
- Application number: 15/736,909
- Filed: 2016-06-15
- Published: 2018-12-20
- Earliest claimed: 2015-06-16
- Assignees: Targent, LLC
- Applicants: Targent, LLC
- Inventors: Stefano Luca Giaffreda; Elena Dichiarante
- Web page: https://patentgrep.com/patent/US20180362427A1

## CPC

- C07C 31/42: Polyhydroxylic acyclic alcohols
- A61K 31/047: having two or more hydroxy groups, e.g. sorbitol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- C07C 29/76: by physical treatment
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.

## Claims

### Claim 1

A crystalline polymorph of 1,6-dibromo-1,6-dideoxy-dulcitol (DBD), wherein the crystalline polymorph exhibits an X-Ray Powder Diffraction Pattern substantially the same as the X-Ray Powder Diffraction Pattern shown in FIG. 1 and/or FIG. 2.

### Claim 2 (depends on 1)

The crystalline polymorph of claim 1, wherein said crystalline polymorph is characterized by:
a. by at least two peaks selected from 19.59° (100,00) and 24.380° (79,52) and 31.260° (8,32) and 34.500° (25,56) and 34.810° (22,83) and 39.260° (23,63) at 2θ±0.1°;
b. by at least three peaks selected from 19.59° (100,00) and 24.380° (79,52) and 31.260° (8,32) and 34.500° (25,56) and 34.810° (22,83) and 39.260 (23,63) at 2θ±0.1°;
c. by at least four peaks selected from 19.59° (100,00) and 24.380° (79,52) and 31.260° (8,32) and 34.500° (25,56) and 34.810° (22,83) and 39.260° (23,63) at 2θ±0.1°; or
d. by at least five peaks selected from 19.59° (100,00) and 24.380° (79,52) and 31.260° (8,32) and 34.500° (25,56) and 34.810° (22,83) and 39.260° (23,63) at 2θ±0.1°; or
e. peaks at 19.59° (100,00) and 24.380° (79,52) and 31.260° (8,32) and 34.500° (25,56) and 34.810° (22,83) and 39.260° (23,63) at 2θ±0.1°.

### Claim 3 (depends on 1)

The crystalline polymorph of claim 1, wherein the crystalline polymorph exhibits an X-Ray Powder Diffraction Pattern substantially the same as the X-Ray Powder Diffraction Pattern described in Table 1.

### Claim 4 (depends on 1)

The crystalline polymorph claim 1, wherein the crystalline polymorph exhibits a beta angle of 96°.

### Claim 5 (depends on 1)

The crystalline polymorph claim 1, wherein the crystalline polymorph exhibits an endothermic point onset at about 184.4° C. and peak at approximately 191° C. as determined by differential scanning calorimetry.

### Claim 6 (depends on 1)

The crystalline polymorph claim 1, wherein the crystalline polymorph is characterized by a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in FIG. 3 and/or FIG. 4.

### Claim 7 (depends on 1)

The crystalline polymorph claim 1, wherein the crystalline polymorph is characterized by a FT-Raman spectrum as shown in Table 3.

### Claim 8 (depends on 1)

A method of making the crystalline polymorph of claim 1, wherein the method comprises:
a. Resuspending DBD in a solution comprising a solvent, wherein the solvent is selected from methanol dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMA), or 1-methyl-2-pyrrolidone;
b. Heating the solution; and
c. Precipitating the crystalline polymorph from the solution.

### Claim 9 (depends on 8)

The method of claim 8, wherein the solvent is methanol.

### Claim 10 (depends on 9)

The method of claim 9, wherein the methanol is a mixture of water and methanol.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mixture comprises 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95% or 96% methanol.

### Claim 12 (depends on 8)

The method of claim 8, wherein the solution is heated to 65° C.

### Claim 13 (depends on 8)

The method of claim 8, wherein the solution is cooled to 5° C.

### Claim 14 (depends on 8)

The method of claim 8, wherein the solution is cooled at a rate of 0.5° C./min.

### Claim 15 (depends on 8)

The method of claim 8, wherein the crystalline polymorph is precipitated using an anti-solvent.

### Claim 16 (depends on 15)

The method of claim 15, wherein the antisolvent is selected from Water, p-Xylene, Dichloromethane, Acetone, Acetonitrile, Ethyl Acetate, Diethyl ether, T-Butyl Methyl Ether, Methanol, Toluene and Chloroform.

### Claim 17 (depends on 8)

The crystalline polymorph produced by the method of claim 8.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the crystalline polymorph of claim 1.

### Claim 19 (depends on 18)

The pharmaceutical composition of claim 18, wherein the crystalline polymorph is formulated with polyethylene glycol (PEG).

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the crystalline polymorph is covalently linked to one or more molecules of PEG.

### Claim 21 (depends on 18)

The pharmaceutical composition claim 18, further comprising a molecule which inhibits cellular DNA-repair mechanisms.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the molecule is a polyADP-ribose polymerase protein (PARP) inhibitor.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the molecule is an alkylating agent.

### Claim 24 (depends on 18)

The pharmaceutical composition of claim 18, further comprising a chemotherapeutic agent.

### Claim 25 (depends on 1)

A method of treating a patient suffering from cancer, wherein the method comprises administering to a patient an effective amount of the crystalline polymorph of claim 1.

### Claim 26 (depends on 25)

The method of claim 25, wherein the patient is suffering from cancer selected from: adenocarcinoma, sarcoma, skin cancer, melanoma, bladder cancer, brain cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, lung cancer, colorectal cancer, cervical cancer, liver cancer, head and neck cancer, esophageal cancer, pancreas cancer, pancreatic ductal adenocarcinoma (PDA), renal cancer, stomach cancer, multiple myeloma, cerebral cancer, lymphoma, melanoma, cancers of the central nervous system, pediatric cancers, pediatric brain cancer, pediatric leukemia, non-small cell lung cancer, gastric cancer, ovarian cancer, or uterine cancer.

### Claim 27 (depends on 25)

The method of claim 25, wherein the cancer is a metastatic cancer.

### Claim 28 (depends on 27)

The method of claim 27, wherein the metastatic cancer has metastasized to the brain.

### Claim 29 (depends on 25)

The method of claim 25, wherein the crystalline polymorph is administered in combination with radiation therapy.

### Claim 30 (depends on 29)

The method of claim 29, wherein the radiation therapy is administered simultaneously, sequentially, or separately with the crystalline polymorph.

### Claim 31 (depends on 25)

The method of claim 25, wherein the method of treating a patient further comprises using gene expression analysis to generate a predictive profile to identify patients most likely to respond to treatment with the crystalline polymorph or the pharmaceutical compositions thereof.
